Understanding the pharmacodynamic changes induced by mitazalimab, a potent CD40 agonistic IgG1 antibody
| Reference number | |
| Coordinator | Alligator Bioscience AB - Alligator Bioscience AB Medicon Village |
| Funding from Vinnova | SEK 442 000 |
| Project duration | March 2023 - October 2023 |
| Status | Completed |
| Venture | MSCA Employment |
| Call | Attract, integrate and retain international excellence |
Important results from the project
To understand the impact of CD40 based immunotherapies, particularly Neo-X-Prime bispecific antibodies, on the immune system and various cancer types using advanced technologies not yet established at Alligator. The study resulted in a manuscript entitled ‘Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody’ by Andersson et al in Cells (September 2023) and presented a poster in September 2023 (CICON).
Expected long term effects
Our research efforts exceeded expectations and culminated in the publication of a manuscript titled ´Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody´ by Andersson et al. in Cells in September 2023. We proudly showcased our findings from preclinical human CD40 transgenic mice bearing MB49 tumors by presenting a poster at a scientific international cancer immunotherapy conference CICON, in September 2023.
Approach and implementation
The following was accomplished: Conducted RNA sequencing and in-depth analysis of experiments within pre-clinical and clinical trial data. Established analysis pipelines and useed publicly available RNA datasets to identify cancer indications with higher expression levels of the target molecules. Developed and tested artificial intelligence-based models using in-house and publicly available datasets which can be correlated with clinical trial data.